Bio-Path Holdings shares surge 89% upon completing Phase 1/1b trial of cancer treatment BP1002 for AML patients.
Bio-Path Holdings (NASDAQ:BPTH) shares increased 89% after the company completed its second dose cohort in Phase 1/1b clinical trial of BP1002, a treatment for refractory/relapsed acute myeloid leukemia (AML) patients, including those resistant to venetoclax. The drug targets the Bcl-2 protein in up to 60% of cancers. Bio-Path hopes to advance to higher doses and reach the combination therapy segment of the Phase 1/1b study.
April 18, 2024
3 Articles